Tharimmune (THAR) Competitors $2.07 -0.03 (-1.43%) (As of 12/20/2024 05:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends THAR vs. AWH, WENA, IPA, IMNN, CRVO, RLMD, TLPH, KZIA, TSBX, and SNSEShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Aspira Women's Health (AWH), ANEW Medical (WENA), ImmunoPrecise Antibodies (IPA), Imunon (IMNN), CervoMed (CRVO), Relmada Therapeutics (RLMD), Talphera (TLPH), Kazia Therapeutics (KZIA), Turnstone Biologics (TSBX), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Aspira Women's Health ANEW Medical ImmunoPrecise Antibodies Imunon CervoMed Relmada Therapeutics Talphera Kazia Therapeutics Turnstone Biologics Sensei Biotherapeutics Tharimmune (NASDAQ:THAR) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability. Does the MarketBeat Community favor THAR or AWH? Aspira Women's Health received 12 more outperform votes than Tharimmune when rated by MarketBeat users. However, 100.00% of users gave Tharimmune an outperform vote while only 18.67% of users gave Aspira Women's Health an outperform vote. CompanyUnderperformOutperformTharimmuneOutperform Votes2100.00% Underperform VotesNo VotesAspira Women's HealthOutperform Votes1418.67%Underperform Votes6181.33% Do analysts recommend THAR or AWH? Tharimmune currently has a consensus target price of $17.00, indicating a potential upside of 721.26%. Aspira Women's Health has a consensus target price of $4.40, indicating a potential upside of 471.43%. Given Tharimmune's stronger consensus rating and higher probable upside, research analysts clearly believe Tharimmune is more favorable than Aspira Women's Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Aspira Women's Health 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in THAR or AWH? 1.2% of Tharimmune shares are held by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are held by institutional investors. 2.4% of Tharimmune shares are held by company insiders. Comparatively, 4.3% of Aspira Women's Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to THAR or AWH? In the previous week, Aspira Women's Health had 3 more articles in the media than Tharimmune. MarketBeat recorded 4 mentions for Aspira Women's Health and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.50 beat Aspira Women's Health's score of 0.00 indicating that Tharimmune is being referred to more favorably in the media. Company Overall Sentiment Tharimmune Positive Aspira Women's Health Neutral Is THAR or AWH more profitable? Tharimmune has a net margin of 0.00% compared to Aspira Women's Health's net margin of -165.07%. Aspira Women's Health's return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -167.63% -130.18% Aspira Women's Health -165.07%N/A -267.23% Which has more volatility & risk, THAR or AWH? Tharimmune has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Which has preferable valuation and earnings, THAR or AWH? Tharimmune has higher earnings, but lower revenue than Aspira Women's Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$9.32MN/AN/AAspira Women's Health$8.96M1.43-$16.69M-$1.20-0.64 SummaryTharimmune beats Aspira Women's Health on 8 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.08M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.015.094.784.78Net Income-$9.32M$151.83M$120.31M$225.60M7 Day Performance-3.27%-2.14%-1.92%-1.23%1 Month Performance-19.14%-4.56%13.65%0.46%1 Year Performance-73.41%8.87%28.34%15.24% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune3.261 of 5 stars$2.07-1.4%$17.00+721.3%-74.0%$3.08MN/A0.002AWHAspira Women's Health1.2122 of 5 stars$0.75+0.6%$4.40+483.6%-69.7%$12.57M$9.15M-0.62110Analyst ForecastWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpIPAImmunoPrecise Antibodies2.9227 of 5 stars$0.43+6.6%$5.00+1,062.8%-69.5%$12.40M$24.07M-0.5280News CoverageIMNNImunon2.3547 of 5 stars$0.84-0.5%$20.50+2,340.5%+9.2%$12.18M$500,000.00-0.4533Analyst ForecastNews CoverageGap UpCRVOCervoMed2.1768 of 5 stars$1.95+2.6%$42.00+2,053.8%-67.1%$12.03M$7.14M0.004Analyst DowngradeAnalyst RevisionHigh Trading VolumeRLMDRelmada Therapeutics4.19 of 5 stars$0.39+5.9%$4.25+993.1%-87.7%$11.73MN/A-0.1310Gap DownHigh Trading VolumeTLPHTalphera2.8842 of 5 stars$0.68+3.8%$4.50+566.7%N/A$11.50M$281,000.00-0.9419Positive NewsKZIAKazia Therapeutics1.7282 of 5 stars$3.33-6.2%$20.00+500.6%-21.6%$11.09M$2.31M0.0012Gap UpTSBXTurnstone Biologics2.8506 of 5 stars$0.47-2.1%$2.13+352.1%-80.2%$10.87M$19.31M-0.1582Positive NewsGap DownSNSESensei Biotherapeutics4.077 of 5 stars$0.43-2.3%$4.33+903.1%-28.6%$10.87MN/A-0.3740Positive NewsGap Down Related Companies and Tools Related Companies Aspira Women's Health Competitors ANEW Medical Competitors ImmunoPrecise Antibodies Competitors Imunon Competitors CervoMed Competitors Relmada Therapeutics Competitors Talphera Competitors Kazia Therapeutics Competitors Turnstone Biologics Competitors Sensei Biotherapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THAR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
